Discover and read the best of Twitter Threads about #REMAP
Most recents (2)
#ACTION RCT results just published @TheLancet: Another negative study of therapeutic #anticoagulantion (TA) in hospitalized people w/ COVID19:
- TA w/ rivaroxaban didn’t improve survival (or *any* endpoint) vs prophylaxis
- more bleeding with TA
1/
thelancet.com/journals/lance…
- TA w/ rivaroxaban didn’t improve survival (or *any* endpoint) vs prophylaxis
- more bleeding with TA
1/
thelancet.com/journals/lance…
The AntiCoagulaTlon cOroNavirus (ACTION) trial was a pragmatic open label RCT at 31 hospitals in 🇧🇷.
It enrolled hospitalized patients with COVID19 & an elevated D-dimer & randomized to TA vs prophylactic anticoagulation (PA).
Aside: not sure how I feel about that acronym...
2/
It enrolled hospitalized patients with COVID19 & an elevated D-dimer & randomized to TA vs prophylactic anticoagulation (PA).
Aside: not sure how I feel about that acronym...
2/
The intervention was TA with either a DOAC (rivaroxaban) if stable or LMWH (enoxaparin 1mg/kg BID) if unstable vs standard of care prophylaxis (UFH or LMWH).
Crossovers were allowed (eg if someone in the PA developed VTE). They adjusted dosing for renal function.
3/
Crossovers were allowed (eg if someone in the PA developed VTE). They adjusted dosing for renal function.
3/
Have you registered for the upcoming CSRC meeting? Join me & others from academia, industry, & regulatory agencies for a follow-up #CardiogenicShock Think Tank on July 24! Register here: bit.ly/2PtxKoE @CardiacSafety
For my part, I'll be talking about the possibility of Randomized, Embedded, Multifactorial, Adaptive, Platform trials and whether they could be a useful tool in generating evidence for the treatment of cardiogenic shock.
This is especially timely in light of the news that the critical care world has just launched the first #REMAP trial in the US:
